Jan Dörrie

Boosting the Activity of Melanoma-Targeting CAR-T Cells in the Presence of Citrate by the Application of Gluconate

Dennis Christoph Harrer, Sebastian Haferkamp, Wolfgang Herr, Maria Mycielska et autres

Background: Chimeric antigen receptor (CAR) T cells achieve cure in the therapy of hematological malignancies. In solid tumors, however, CAR-T cells face an immunosuppressive tumor microenvironment (TME) which crucially impedes their cytotoxic capacities. Citrate accumulating in the TME is a crucial metabolite …

de (code pays fourni par la source)

Transforming tumor cells into professional antigen-presenting cells using poly(β-amino ester) nanoparticles to deliver CD80-encoding mRNA

Amanda Katharina Binder, Franziska Bremm, Niklas Feuchter, Antoni Torres-Coll et autres

Efficient delivery of CD80 mRNA by pBAE nanoparticles induces CD80 expression on tumor cells, enabling them to function as antigen-presenting cells and trigger CD8 + T cell–mediated anti-tumor immunity.

de, es (code pays fourni par la source)

Boosting the Activity of Melanoma-Targeting CAR-T Cells in the Presence of Citrate by the Application of Gluconate

Dennis Christoph Harrer, Sebastian Haferkamp, Wolfgang Herr, Maria E. Mycielska et autres

Background: Chimeric antigen receptor (CAR) T cells achieve cure in the therapy of hematological malignancies. In solid tumors, however, CAR-T cells face an immunosuppressive tumor microenvironment (TME) which crucially impedes their cytotoxic capacities. Citrate accumulating in the TME is a crucial metabolite …

STINGing Cancer: Development, Clinical Application, and Targeted Delivery of STING Agonists

Yannick Gabriel Nerdinger, Amanda Katharina Binder, Franziska Bremm, Niklas Feuchter et autres

As cancer incidence continues to rise and conventional therapies remain of limited effectiveness, the search for novel and innovative cancer treatments is ongoing. In recent years, immunotherapies, including checkpoint inhibitors and cell-based approaches such as CAR-T cell therapy, have revolutionized the treatment …

de (code pays fourni par la source)

Enhanced diagnostic potential of CSPG4 in melanoma and nevi: a comparative study with PRAME , CDC7 and Ki67

Elias A. T. Koch, Ramona Erber, Michael A. Erdmann, Markus Vincent Heppt et autres

Abstract Chondroitin sulfate proteoglycan 4 (CSPG4) is a promising target for melanoma immunotherapy, but its expression in benign melanocytic lesions and its diagnostic value remain unexplored. This study assessed CSPG4 expression in benign nevi (BN), dysplastic nevi (DN), and superficial spreading melanomas …

de, bd (code pays fourni par la source)

Case Report: Personalized peptide-based immunization in an advanced-stage prostate cancer patient with bone metastasis

Nils Heinrich Thoennissen, Mari Carmen Martos-Contreras, Mehdi Manoochehri, Mauro S. Nogueira et autres

metastatic hormone-sensitive prostate cancer (mHSPC) case, which benefited from our personalized peptide immunization named BioInformatic Tumor Address Peptides (BITAP) in a monotherapeutic setting. Our in-house bioinformatics pipeline involved identifying somatic variations, analyzing their expression, and computationally predicting novel epitopes from both metastatic …

de (code pays fourni par la source)

Rendering NK Cells Antigen-Specific for the Therapy of Solid Tumours

Carina A. Doeppner, Amanda Katharina Binder, Franziska Bremm, Niklas Feuchter et autres

Cancer remains one of the leading causes of death worldwide. New treatments like immunotherapy-especially checkpoint inhibitors and CAR-T cell therapy-have improved outcomes for some patients. However, these therapies often struggle to treat solid tumours effectively. Natural killer (NK) cells are part of …

de (code pays fourni par la source)

Chimeric Antigen Receptor (CAR) T Cells Releasing Soluble SLAMF6 Isoform 2 Gain Superior Anti-Cancer Cell Functionality in an Auto-Stimulatory Fashion

Dennis Christoph Harrer, Tim Schlierkamp-Voosen, Markus Barden, Hong Pan et autres

T cells equipped with chimeric antigen receptors (CARs) have evolved into an essential pillar of lymphoma therapy, reaching second-line treatment. In solid cancers, however, a dearth of lasting CAR T cell activation poses the major obstacle to achieving a substantial and durable …

de (code pays fourni par la source)

The Influence of Indisulam on Human Immune Effector Cells: Is a Combination with Immunotherapy Feasible?

Lisa Arnet, Lisabeth Emilius, Maria Carmo-Fonseca, Carola Berking et autres

Background: As a modulator of pre-mRNA splicing, the anti-cancer agent indisulam can induce aberrantly spliced neoantigens, enabling immunologic anti-tumor activity. Consequently, combining indisulam with immunotherapy is expected to be a promising novel approach in cancer therapy. However, a prerequisite for such a …

de, pt (code pays fourni par la source)

Avelumab mediates antibody‐dependent cellular cytotoxicity against monocyte‐derived dendritic cells through natural killer cells

Tatjana Sauerer, Franziska Bremm, Amke C. Beenen, Lukas Heger et autres

Avelumab mediates antibody-dependent cellular cytotoxicity against monocyte-derived

de (code pays fourni par la source)

Loading of CAR‐T cells with magnetic nanoparticles for controlled targeting suppresses inflammatory cytokine release and switches tumor cell death mechanism

Felix Pfister, Lucas R. Carnell, Philipp Boosz, Niels Schaft et autres

Therapies against hematological malignancies using chimeric antigen receptors (CAR)-T cells have shown great potential; however, therapeutic success in solid tumors has been constrained due to limited tumor trafficking and infiltration, as well as the scarcity of cancer-specific solid tumor antigens. Therefore, the …

de, gb (code pays fourni par la source)

The Biology of Dendritic Cells: In Health and Disease

Dmytro Royzman, Jan Dörrie, Anita Heiß, Pia Sinner et autres

de (code pays fourni par la source)